FDA investigates risk of secondary lymphomas after CAR-T immunotherapy

Lancet Oncol. 2024 Jan;25(1):21. doi: 10.1016/S1470-2045(23)00631-9. Epub 2023 Dec 7.
No abstract available

MeSH terms

  • Humans
  • Immunotherapy / adverse effects
  • Immunotherapy, Adoptive / adverse effects
  • Lymphoma* / therapy
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen*

Substances

  • Receptors, Chimeric Antigen
  • Receptors, Antigen, T-Cell